semaglutide and liver problems Focus on 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis - Petta - 2025 - International Semaglutide-Induced Liver Injury - PMC

Regulates blood sugar and lowers diabetes risk

Trials 23 , 170 (2022)

For women with pre-existing conditions such as PCOS, endometriosis, or thyroid disorders, it is particularly important to work closely with your healthcare provider to distinguish between expected improvements in cycle regularity and concerning changes that may require investigation

In Phase 3 data: 20.7% average weight loss (72 weeks) vs ~15% with standard 2.4 mg Wegovy 14.1% weight loss in Type 2 diabetes patients As Jason Brett, principal U.S

Inability to maintain adequate nutrition : If digestive symptoms prevent you from eating sufficient calories or taking other essential medications, discuss this with your healthcare team promptly